Literature DB >> 17675886

A suppository Chinese medicine (xilei-san) for refractory ulcerative proctitis: a pilot clinical trial.

Ken Fukunaga, Nobuyuki Hida, Kunio Ohnishi, Yoshio Ohda, Koji Yoshida, Takeshi Kusaka, Yoshio Jinno, Kazuko Nagase, Shiro Nakamura, Muneo Kadobayashi, Hiroto Miwa, Takayuki Matsumoto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17675886     DOI： 10.1159/000106755

Source DB:  PubMed          Journal:  Digestion        ISSN： 0012-2823            Impact factor:   3.216


× No keyword cloud information.
  5 in total

Review 1.  Indole compounds may be promising medicines for ulcerative colitis.

Authors:  Shinya Sugimoto; Makoto Naganuma; Takanori Kanai
Journal:  J Gastroenterol       Date:  2016-05-09       Impact factor: 7.527

2.  Therapeutic efficacy of the Qing Dai in patients with intractable ulcerative colitis.

Authors:  Hideo Suzuki; Tsuyoshi Kaneko; Yuji Mizokami; Toshiaki Narasaka; Shinji Endo; Hirofumi Matsui; Akinori Yanaka; Aki Hirayama; Ichinosuke Hyodo
Journal:  World J Gastroenterol       Date:  2013-05-07       Impact factor: 5.742

3.  Xilei san ameliorates experimental colitis in rats by selectively degrading proinflammatory mediators and promoting mucosal repair.

Authors:  Yongbiao Hao; Kazuko Nagase; Kazutoshi Hori; Shenglan Wang; Yoko Kogure; Ken Fukunaga; Shinichiro Kashiwamura; Satoshi Yamamoto; Shiro Nakamura; Junxiang Li; Hiroto Miwa; Koichi Noguchi; Yi Dai
Journal:  Evid Based Complement Alternat Med       Date:  2014-07-10       Impact factor: 2.629

4.  Acute pancreatitis associated with indigo naturalis in pediatric severe Crohn's disease.

Authors:  Hyeon-A Kim; Hyo-Rim Suh; Ben Kang; Byung-Ho Choe
Journal:  Intest Res       Date:  2018-10-16

5.  Efficacy and safety of short-term therapy with indigo naturalis for ulcerative colitis: An investigator-initiated multicenter double-blind clinical trial.

Authors:  Kan Uchiyama; Shinichiro Takami; Hideo Suzuki; Kiyotaka Umeki; Satoshi Mochizuki; Nobushige Kakinoki; Junichi Iwamoto; Yoko Hoshino; Jun Omori; Shunji Fujimori; Akinori Yanaka; Yuji Mizokami; Toshifumi Ohkusa
Journal:  PLoS One       Date:  2020-11-05       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.